Mar 21, 2018
Back in February, the Enterprise Europe Network team at RTC north helped to deliver a funded Accelerator Programme visit for companies operating in the Cell and Gene Therapy sector in partnership with Innovate UK. The aim of the visit was to help attendees further develop their innovations through in-market partnerships, collaborations and knowledge exchange with businesses and research organisations based in Japan.
Cell and gene therapy has become a priority area for the Japanese government. Japan is focused on the need to collaborate with the national and international industry to pursue the commercialisation of new scientific discoveries. This, in parallel with the implementation of the New Japanese Regulatory Frameworks for Clinical Research and Marketing Authorisation of Gene Therapy and Cellular Therapy Products speeding up getting products to the market and facilitating the understanding of regulations by foreign operators promoting translational cooperation makes Japan an attractive market in this field. Licensing, partnering, outsourcing, development and commercialisation opportunities abound, but collaboration is absolutely critical to the success of each one.
All together, we accompanied thirteen companies with innovative therapies, products, processes and services in the areas of cell and gene therapy to Japan, with the aim to create some partnerships through pre-arranged meetings. Our attendees were given the opportunity to stand up and give a short presentation on their company and business needs, learn about market opportunities and business culture, attend on-site visits to local facilities of interest, and also had the opportunity to attend the Regenerative Medicine Expo and Conference at Medical Japan 2018.